Barcelona, 3 July 2018: Following concerns over many years that hormonal stimulation of the ovaries necessary for IVF may increase the risk of ovarian cancer, a nationwide cohort study from Denmark has now concluded that any perceived increase in risk is actually a statistical bias resulting from vigilant diagnosis at the time of treatment. The investigators were unable to make any causal association between the treatment and fertility drugs used and any excess risk of ovarian cancer.
The study matched every woman having IVF in Denmark between 1994 and 2015 with ten women from the background population and in its analysis found that assisted reproduction treatment (ART) "was not associated with a long-term increased risk of ovarian cancer which would be expected if caused by ovarian stimulating hormones".
Results of this study, which finally included 58,472 women treated with IVF or ICSI and 549,210 non-treatment women, are presented today at the 34th Annual Meeting of ESHRE in Barcelona by gynaecologist Professor Anja Pinborg of the Fertility Department at Rigshospitalet, Copenhagen University Hospital, in Denmark. Each of the women were followed-up until a first cancer diagnosis, death or end of study period in 2015.
Results did show a slightly higher overall risk of ovarian cancer among the ART women (0.11%) than among the non-ART controls (0.06%). However, the analysis also showed comparably higher rates of ovarian cancer in women who were nulliparous and in the ART women who had a female cause of infertility. By contrast, ART treatment where the cause of infertility was in the male partner (or even unexplained) was associated with a lower risk of ovarian cancer. It was these anomalies in the analysis which indicated that any observed increase in risk was not associated with stimulation of the ovaries per se but more with parity status, cause of infertility and vigilance.
There has long been a concern that the fertility drugs used in assisted reproduction were a risk factor for ovarian cancer, though any causal biological mechanism was never fully explained. This view is based on an observation that increased ovarian activity (such as in nulliparity or a late menopause) increases the risk. By contrast, pregnancy or use of oral contraceptives, which both inhibit ovarian activity, have been shown to reduce the risk. Nevertheless, and despite these proposals, increasing age and genetic factors (such as an inherited mutation of the two BRCA genes) remain the most clearly associated risk factors, although the disease remains complex in its cause and late in its diagnosis.
This population study, which cross-linked the comprehensive national cancer and reproductive health registries of Denmark, found that any excess risk in the ART women was at its highest in the first two years after treatment but this excess risk gradually declined over the study period – and at 12 years after treatment was similar to that of the general population background group. "This pattern," say the authors, "suggests an influence of detection bias while undergoing ART treatment."
"We found that the higher risk of ovarian cancer among women having assisted reproduction treatment was only present among those with diagnosed female infertility," said Pinborg. "And in a general population we saw that ovarian stimulation does not seem to increase the risk of ovarian cancer."
She described the results as "reassuring", adding: "I would advise infertile women contemplating ART treatment to go ahead. Ovarian stimulation itself is not introducing any excess risk of ovarian cancer." She also noted that, while the relative risks appear high among some groups of women, the absolute risk of beng diagnosed with ovarian cancer remain small.
###
Abstract O-193, Tuesday 3 July 2018
Assisted reproductive technology (ART) treatment and risk of ovarian cancer
Assisted reproduction and risk of ovarian cancer
1. Several (but not all) studies in the past have reported an increased risk of ovarian cancer associated with ART; however, these findings are inconsistent and usually based on very few diagnosed cases. Difficulty in risk assessment is compounded by detection often at a late stage (without symptoms in the early stages) and a latency from initiation to diagnosis of 30-40 years.
2. There was a scare in the 1990s when several epidemiological studies reported an association between fertility drugs and the development of ovarian cancer (see for example, Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. Am J Epidemiol 1992; 136: 1184-203. These studies prompted further studies, which failed to confirm any added risk. These later studies, which are described as "reassuring", are reviewed in Diergaarde B, Kurta ML. Use of fertility drugs and risk of ovarian cancer. Curr Opin Obstet Gynecol 2015; 26: 125-129.
3. A 2015 study based on the UK's HFEA database had similar findings over time to this Danish cohort study, which suggested that female infertility, rather than ovarian stimulation, was behind any excess risk of ovarian cancer.
* When obtaining outside comment, journalists are requested to ensure that their contacts are aware of the embargo on this release.
For further information on the details of this press release, contact:
Christine Bauquis at ESHRE
Mobile: +32 (0)499 25 80 46
Email: [email protected]
Media Contact
Christine Bauquis
[email protected]
32-499-258-046
@ESHRE
https://www.eshre.eu/
